Download PDF
Exp Clin Endocrinol Diabetes 2022; 130(09): 627-632
DOI: 10.1055/a-1782-9389
Article

Adjustment of Anti-Hyperglycaemic Agents During Bowel Preparation for Colonoscopy in Patients with Diabetes

Karsten Müssig 
1   Department of Internal Medicine, Gastroenterology and Diabetology, Niels Stensen Hospitals, Franziskus Hospital Harderberg, Georgsmarienhütte, Germany
,
Henning E. Adamek
2   Second Department of Internal Medicine (Gastroenterology, Hepatology, Diabetology), Klinikum Leverkusen, Leverkusen, Germany
› Author Affiliations Funding This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objective Due to the growing diabetes pandemic, the number of colonoscopies performed in patients with diabetes is steadily rising. However, recommendations on adjustments of anti-hyperglycaemic agents (AHG) during bowel preparation for colonoscopy are limited.

Methods A total of nine articles were revealed on a PubMed search using the search terms “diabetes” and “colonoscopy”, “sigmoidoscopy”, “endoscopy”, “endoscopic intervention”, “endoscopic invasive diagnostics”, “endoscopic surgery”, or “diabetes care in the hospital” and manual screening of the references of the articles reporting on AHG adjustment during bowel preparation.

Results Regular glucose measurements and the opportunity to contact the diabetes team were commonly advised. Recommendations also agreed that all oral AHG and short-acting insulin should be omitted when patients are on clear fluids. Recent studies suggest discontinuation of sodium-glucose cotransporter-2 (SGLT2) inhibitors even three days before the colonoscopy. In contrast, recommendations differed regarding adjustment of basal insulin depending on diabetes type and time point in relation to the intervention.

Conclusions While discontinuation of oral AHG and short-acting insulin during bowel preparation for colonoscopy is generally accepted, recommendations on the adaptation of basal insulin follow different approaches.

Key words

Humans - sodium - glucose transporter 2 inhibitors - insulin - short-acting - adaptation - physiological - colonoscopy - PubMed - glucose


Publication History

Received: 29 November 2021
Received: 21 February 2022

Accepted: 23 February 2022

Article published online:
31 March 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Bray F, Ferlay J, Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424
    CrossrefPubMedGoogle Scholar
  • 2 GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117-171
    CrossrefPubMedGoogle Scholar
  • 3 Lin X, Xu Y, Pan X. et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: An analysis from 1990 to 2025. Sci Rep 2020; 10: 14790
    CrossrefPubMedGoogle Scholar
  • 4 Peeters PJ, Bazelier MT, Leufkens HG. et al. The risk of colorectal cancer in patients with type 2 diabetes: Associations with treatment stage and obesity. Diabetes Care 2015; 38: 495-502
    CrossrefPubMedGoogle Scholar
  • 5 Liu PH, Wu K, Ng K. et al. Association of obesity with risk of early-onset colorectal cancer among women. JAMA Oncol 2019; 5: 37-44
    CrossrefPubMedGoogle Scholar
  • 6 Mokdad AH, Ford ES, Bowman BA. et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76-79
    CrossrefPubMedGoogle Scholar
  • 7 Shaukat A, Mongin SJ, Geisser MS. et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013; 369: 1106-1114
    CrossrefPubMedGoogle Scholar
  • 8 Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: Systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ 2014; 348: g2467
    CrossrefPubMedGoogle Scholar
  • 9 Schreuders EH, Ruco A, Rabeneck L. et al. Colorectal cancer screening: A global overview of existing programmes. Gut 2015; 64: 1637-1649
    Google Scholar
  • 10 Joseph DA, Meester RG, Zauber AG. et al. Colorectal cancer screening: Estimated future colonoscopy need and current volume and capacity. Cancer 2016; 122: 2479-2486
    CrossrefPubMedGoogle Scholar
  • 11 Shenbagaraj L, Thomas-Gibson S, Stebbing J. et al. Endoscopy in 2017: A national survey of practice in the UK. Frontline Gastroenterol 2019; 10: 7-15
    CrossrefPubMedGoogle Scholar
  • 12 Mahmood S, Farooqui SM, Madhoun MF. Predictors of inadequate bowel preparation for colonoscopy: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2018; 30: 819-826
    CrossrefPubMedGoogle Scholar
  • 13 Piper MS, Saad RJ. Diabetes Mellitus and the Colon. Curr Treat Options Gastroenterol 2017; 15: 460-474
    CrossrefPubMedGoogle Scholar
  • 14 Johnson DA, Barkun AN, Cohen LB. et al. Optimizing adequacy of bowel cleansing for colonoscopy: Recommendations from the US multi-society task force on colorectal cancer. Gastroenterology 2014; 147: 903-924
    CrossrefPubMedGoogle Scholar
  • 15 Lewandowski K, Rydzewska G, Ledwoń TK. Preparation for endoscopic examinations in patients with diabetes and hypoglycaemia. Prz Gastroenterol 2021; 16: 297-305
    PubMedGoogle Scholar
  • 16 Lee B, Jain D, Rajala M. A survey of peri-colonoscopy management of anti-diabetic medications. Clin Endosc 2020; 53: 623-626
    CrossrefPubMedGoogle Scholar
  • 17 Australian Diabetes Society. (2012, July 1).. Peri-operative diabetes management Retrieved from. https://diabetessociety.com.au/documents/PerioperativeDiabetesManagementGuidelinesFINALCleanJuly2012.pdf Accessed January 31, 2022
    PubMedGoogle Scholar
  • 18 Australian Diabetes Society. (2020, September 1).. Alert update September 2020. Periprocedural Diabetic Ketoacidosis (DKA) with SGLT2 Inhibitor Retrieved from. https://diabetessociety.com.au/downloads/20201015%20ADS_DKA_SGLT2i_Alert_update_Sept_2020.pdf Accessed January 31, 2022
    PubMedGoogle Scholar
  • 19 Hochberg I, Segol O, Shental R. et al. Antihyperglycemic therapy during colonoscopy preparation: A review and suggestions for practical recommendations. United European. Gastroenterol J 2019; 7: 735-740
    PubMedGoogle Scholar
  • 20 Meyer EJ, Mignone E, Hade A. et al. Periprocedural euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter 2 inhibitor therapy during colonoscopy. Diabetes Care 2020; 43: e181-e184
    CrossrefPubMedGoogle Scholar
  • 21 American Diabetes Association. 15. Diabetes care in the hospital: Standards of medical care in diabetes-2021. Diabetes Care 2021; 44: S211-S220
    CrossrefPubMedGoogle Scholar
  • 22 Hamblin PS, Wong R, Ekinci EI. et al. Capillary ketone concentrations at the time of colonoscopy: A cross-sectional study with implications for SGLT2 inhibitor-treated type 2 diabetes. Diabetes Care 2021; 44: e124-e126
    PubMedGoogle Scholar
  • 23 Thiruvenkatarajan V, Meyer EJ, Jesudason D. Comment on Hamblin et al. Capillary ketone concentrations at the time of colonoscopy: A cross-sectional study with implications for SGLT2 inhibitor-treated type 2 diabetes. Diabetes Care 2021; 44: e124-e126 Diabetes Care 2022; 45: e15-e16
    PubMedGoogle Scholar
  • 24 Hamblin PS, Wong R, Ekinci EI. et al. Response to comment on Hamblin et al. Capillary ketone concentrations at the time of colonoscopy: A cross-sectional study with implications for SGLT2 inhibitor-treated type 2 diabetes. Diabetes Care 2021; 44: e124-e126 Diabetes Care 2022; 45: e17-e18
    CrossrefPubMedGoogle Scholar
  • 25 Yu F, Guo Y, Wang H. et al. Type 2 diabetes mellitus and risk of colorectal adenoma: A meta-analysis of observational studies. BMC Cancer 2016; 16: 642
    CrossrefPubMedGoogle Scholar
  • 26 Li M, Olver I, Keefe D. et al. Pre-diagnostic colonoscopies reduce cancer mortality – results from linked population-based data in South Australia. BMC Cancer 2019; 19: 856
    CrossrefPubMedGoogle Scholar
  • 27 McDonagh TA, Metra M, Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022; 24: 4-131
    CrossrefPubMedGoogle Scholar
  • 28 Herrington WG, Frankel AH. (2021, October18). UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease. Retrieved from https://ukkidney.org/sites/renal.org/files/UKKA%20guideline_SGLT2i%20in%20adults%20with%20kidney%20disease%20v1%2018.10.21.pdfAccessed January 31, 2022
    PubMed
  • 29 Takeishi S, Mori A, Fushimi N. et al. Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring. J Diabetes Investig 2016; 7: 374-380
    CrossrefPubMedGoogle Scholar
  • 30 Sayın P, Türk HŞ, Işıl CT. et al. Is it necessary to measure blood glucose level before and after colonoscopy in diabetic and nondiabetic patients?. Sisli Etfal Hastan Tip Bul 2019; 53: 413-418
    PubMedGoogle Scholar
  • 31 Hornor MA, Duane TM, Ehlers AP. et al. American College of Surgeons’ guidelines for the perioperative management of antithrombotic medication. J Am Coll Surg 2018; 227: 521-536.e1
    CrossrefPubMedGoogle Scholar